Rapport Therapeutics, Inc. Temporary Equity, Liquidation Preference
Rapport Therapeutics, Inc. (RAPP) had Temporary Equity, Liquidation Preference of $250.18 million as of 2024-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Balance Sheet › Equity › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2025-05-08
- 2024-03-31: Temporary Equity, Liquidation Preference $250.18M.
- 2023-12-31: Temporary Equity, Liquidation Preference $186.18M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2024-03-31 | $250.18M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $186.18M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |